持有300111必看！向日葵投资者索赔通道已开，亏损速登记

Core Viewpoint - The announcement from Zhejiang Sunflower Health Technology Co., Ltd. (stock code: 300111) regarding a formal investigation by the China Securities Regulatory Commission (CSRC) due to misleading statements and violations of information disclosure has triggered a significant compensation claim process affecting 130,000 shareholders [1][2]. Group 1: Company Background and Events - On September 22, 2025, Sunflower announced a restructuring plan to acquire 100% of Xipu Materials and 40% of Beid Pharmaceutical, aiming to enter the semiconductor materials sector, which led to a surge in stock price and an increase in shareholder numbers from 60,000 to 130,000 within three months [1]. - A deep investigation by Zhitong Finance on December 25, 2025, revealed that Xipu Materials' core production capacity was fabricated, with the factories not operational and lacking necessary permits, contradicting the restructuring proposal [2]. - Following the investigation, the Shenzhen Stock Exchange issued a notice requiring Sunflower to verify the authenticity of its production capacity and related transactions, but the company failed to provide satisfactory responses, leading to the CSRC's formal investigation and the termination of the restructuring plan on January 14, 2026 [2]. Group 2: Market Reaction and Financial Impact - The stock price of Sunflower plummeted following the investigation, with a 10% drop on December 26, 2025, and an additional 10% decline after the announcement of the investigation, culminating in a 20% limit down on January 15, 2026, resulting in significant losses for investors [2]. - As of February 2, 2026, the stock price was reported at 4.39 yuan, a substantial decrease from the peak value during the restructuring hype, indicating severe financial repercussions for investors [2]. Group 3: Compensation Process - Investors who purchased Sunflower shares between September 22, 2025, and December 25, 2025, and held them through the latter date are eligible to file for compensation without upfront legal fees, as per the provisions of the Securities Law of the People's Republic of China [3]. - A call to action for affected shareholders to gather trading records and other necessary documentation to pursue claims through legal channels has been emphasized, with guidance available from legal professionals [3].